Kristen Sanfilippo is a Hematology physician affiliated with Washington University in St. Louis. OpenAlex indexes 207 publications with 2,829 citations (h-index 28).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4500 Forest Park Ave
Div Im Hematology, 6th Fl
Saint Louis, MO 631082114
Telephone
314-362-7216Provider last certified this registry record 8 Sept 2025.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20251 payment
- Novo Nordisk IncProgram year20251 payment
- SOBI, INCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
95.6%Factor Xa inhibitor52%Eliquis79%Xarelto21%Part D≥50 patientsVitamin K antagonist34.9%Warfarin Sodium100%Part D≥18 patients+ 2 more classes in this area
Nervous system
4.4%Opioid Agonist4.4%Oxycodone Hcl50%Morphine Sulfate Er50%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2017–2026 per NIH RePORTER. The latest:
- Prediction of Anticoagulant-Related Bleeding Risk in Patients with Cancer
Washington University
FY2026$389,391R01HL166386 - Prediction of Anticoagulant-Related Bleeding Risk in Patients with Cancer
Washington University
FY2025$389,391R01HL166386 - Prediction of Anticoagulant-Related Bleeding Risk in Patients with Cancer
Washington University
FY2024$392,869R01HL166386
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis
European Heart Journal
2025 - Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial
Journal of Thrombosis and Haemostasis
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Ley, MD
Washington University in St. Louis
David Gutmann, MD
Washington University in St. Louis
Randall Bateman, MD
Washington University in St. Louis
Victoria Fraser, MD
Washington University in St. Louis
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”